Clinical Trials
- Lung
Saracatinib (AZD0530) in the Treatment of Patients with Idiopathic Pulmonary Fibrosis
- Ages40 years and older
- GenderBoth
- Orthopaedics, Muscle & Bone
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
- Ages40 years - 80 years
- GenderBoth
- Immune System
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis
- Immune System
Characterization of SSc-ILD patients and linkage to clinical outcomes
- Ages18 years and older
- GenderBoth
- Arthritis
Yale Rheumatology Program Patient Registry and Bio-Repository
- Ages18 years - 99 years
- GenderBoth
- Diseases of the Respiratory Systems
A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis
- Ages18 years and older
- GenderBoth
- Phase 1 Cancers
Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors
- Lung Cancer
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Heart/Cardiovascular
Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS- RCT)
- Ages18 years and older
- GenderBoth
- Phase 1 Cancers
First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid Tumors